Table 2. Clinical characteristics of 85 patients with both EGFR-mutant advanced NSCLC and T2DM.
| Characteristic | First-line EGFR-TKIs | Second-line osimertinib | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Metformin use | P | Total | Metformin use | P | ||||||
| N=85 | Yes, N=28 | No, N=57 | N=22 | Yes, N=10 | No, N=12 | ||||||
| Gender, N (%) | |||||||||||
| Female | 49 (57.6) | 16 (57.1) | 33 (57.9) | 0.876 | 14 (63.6) | 6 (60.0) | 8 (66.7) | 0.746 | |||
| Male | 36 (42.4) | 12 (42.9) | 23 (42.1) | – | 8 (36.4) | 4 (40.0) | 4 (33.3) | ||||
| Age (years) | |||||||||||
| Median | 65 | 65 | 65 | 0.760 | 66 | 68 | 66 | 0.680 | |||
| Range | 36-84 | 45-78 | 36-84 | – | 36-84 | 50-78 | 36-84 | ||||
| Histology, N (%) | |||||||||||
| Adenocarcinoma | 77 (90.6) | 25 (89.3) | 52 (91.2) | 0.349 | 20 (90.9) | 9 (90.0) | 11 (91.7) | 0.892 | |||
| Squamous | 1 (1.2) | 1 (3.6) | 0 (0.0) | – | 0 (0) | 0 (0.0) | 0 (0) | – | |||
| NSCLC-NOS | 7 (8.2) | 2 (7.1) | 5 (8.8) | – | 2 (9.1) | 1 (10.0) | 1 (8.3) | – | |||
| ECOG PS, N (%) | – | – | – | – | – | – | – | – | |||
| 0–1 | 75 (88.2) | 24 (85.7) | 51 (89.5) | 0.883 | 19 (86.4) | 8 (80.0) | 11 (91.7) | 0.571 | |||
| 2–3 | 10 (11.8) | 4 (14.3) | 6 (10.5) | – | 3 (13.6) | 2 (20.0) | 1 (8.3) | – | |||
| Stage at diagnosis, N (%) | |||||||||||
| IB–IIIA | 7 (8.2) | 4 (14.3) | 3 (5.3) | 0.316 | 3 (13.6) | 2 (20.0) | 1 (8.3) | 0.571 | |||
| IIIB–IV | 78 (91.8) | 24 (85.7) | 54 (94.7) | – | 19 (86.4) | 8 (80.0) | 11 (91.7) | – | |||
| Smoking, N (%) | |||||||||||
| Never | 60 (70.6) | 20 (71.4) | 40 (70.2) | 0.905 | 15 (68.2) | 6 (60.0) | 9 (75.0) | 0.652 | |||
| Current/former | 25 (29.4) | 8 (28.6) | 17 (29.8) | – | 7 (31.8) | 4 (40.0) | 3 (25.0) | – | |||
| EGFR status, N (%) | – | – | – | – | – | – | – | – | |||
| 19DEL | 37 (43.5) | 12 (42.9) | 25 (43.9) | 0.930 | 9 (40.9) | 4 (40.0) | 5 (41.7) | 0.937 | |||
| L858R | 48 (56.5) | 16 (57.1) | 32 (56.1) | – | 13 (59.1) | 6 (60.0) | 7 (58.3) | – | |||
| TKIs, N (%) | – | – | – | – | – | – | – | – | |||
| Gefitinib | 53 (62.4) | 15 (53.6) | 38 (66.7) | 0.256 | 13 (59.1) | 6 (60.0) | 7 (58.3) | 0.981 | |||
| Erlotinib | 11 (12.9) | 3 (10.7) | 8 (40.0) | – | 2 (9.1) | 1 (10.0) | 1 (8.3) | – | |||
| Icotinib | 21 (24.7) | 10 (35.7) | 11 (19.3) | – | 7 (31.8) | 3 (30.0 | 4 (33.3) | – | |||
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; NSCLC-NOS, non-small cell lung cancer-not otherwise specified; ECOG PS, Eastern Cooperative Oncology Group performance status.